Introduction
The coronavirus disease (COVID-19) contributed to a worldwide crisis causing major morbidity and mortality as well as devastating economic and social consequences. As for previous infectious diseases, vaccination is considered vital to control the COVID-19 pandemic. With unprecedented speed, several vaccines were developed and licensed internationally. By July 2021, the U.S. Food and Drug Administration (FDA) approved two mRNA-based vaccines: mRNA1273 (Moderna) and BNT162b2 (BioNTech/Pfizer); and one recombinant vector-based vaccine: adenovirus type 26 vector Covid-19 Vaccine Janssen (Johnson&Johnson).  In addition to previous vaccines, the European Medicines Agency (EMA) also approved the recombinant chimpanzee adenoviral vector vaccine ChAdOx1 nCoV-19 (Vaxzevria /previously COVID-19 vaccine AstraZeneca).
Several surveys have discovered various systematic, focal, and organ-specific adverse effects resulting from different vaccines(1)(2). Among several side effects of vaccines, concerns about unusual thrombotic events following COVID-19 vaccination with AstraZeneca started to grow early in March 2021. Several researchers from Norway(3), Germany(4), and United Kingdom(5) reported a group of patients who had been admitted within three weeks of AstraZeneca vaccine inoculation with thrombocytopenia and cerebral venous sinus thrombosis (CVST). In terms of neurological adverse effects, headache, decrease in mental attention, paralysis or weakness of extremities, dizziness, paraesthesia, and numbness were the most prevalent ones(1)(6). Complaints such as loss of consciousness, seizures, and facial weakness were rare, though(1). Skin manifestation of COVID-19 vaccination ranged wide spectrum including chilblain‐like, urticarial, vesicular, maculopapular, livedoid and vasculitic lesions(7)(8). Thus, it seems that COVID-19 vaccines’ have a wide spectrum of adverse effects and further investigations are needed to help clinicians for better diagnosis and management.
The current paper aims to report three post-AstraZeneca COVID-19 vaccination events causing hospitalization, including encephalopathy, CVST, and Leukocytoclastic Vasculitis (LCV).